A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2016
At a glance
- Drugs SM 04554 (Primary)
- Indications Alopecia; Male pattern baldness
- Focus Therapeutic Use
- Sponsors Samumed
- 07 Mar 2016 Results presented at the 74th Annual Meeting Of The American Academy Of Dermatology (AAD), according to a Samumed media release.
- 04 Dec 2015 Results published in Samumed media release.
- 04 Dec 2015 Primary endpoint has been met (Change in non-vellus hair count), as per Samumed media release.